Cellseed Inc. | Cash Flow

Fiscal year is January-December. All values JPY Thousands.
2013
2014
2015
2016
2017
Net Income before Extraordinaries
581,921.00
580,645.00
531,523.00
1,415,613.00
964,184.00
Depreciation, Depletion & Amortization
1,389.00
2,536.00
9,453.00
8,084.00
4,726.00
Other Funds
31,284.00
5,320.00
22,544.00
576,923.00
54,771.00
Funds from Operations
549,248.00
583,429.00
544,614.00
830,606.00
1,014,226.00
Changes in Working Capital
49,738.00
25,715.00
131,055.00
21,421.00
267,053.00
Net Operating Cash Flow
499,510.00
609,144.00
675,669.00
852,027.00
747,173.00
Capital Expenditures
-
1,692.00
245,132.00
343,622.00
5,004.00
Sale of Fixed Assets & Businesses
-
-
9,719.00
-
-
Purchase/Sale of Investments
-
-
39,590.00
625.00
-
Net Investing Cash Flow
7,233.00
1,491.00
275,003.00
342,997.00
5,004.00
Net Financing Cash Flow
2,886,416.00
838,541.00
151,697.00
232,650.00
1,040,707.00
Net Change in Cash
2,449,201.00
232,735.00
853,856.00
1,011,216.00
293,833.00
Free Cash Flow
499,510.00
610,670.00
920,801.00
1,195,649.00
751,462.00
Other Sources
14,533.00
228.00
-
-
-
Change in Capital Stock
2,886,416.00
838,541.00
151,697.00
232,650.00
1,040,707.00
Exchange Rate Effect
55,062.00
4,829.00
54,881.00
48,842.00
5,303.00
Other Uses
7,300.00
27.00
-
-
-

About Cellseed

View Profile
Address
Telecom Center Building, 15/F
Tokyo Tokyo 135
Japan
Employees -
Website http://www.cellseed.com
Updated 09/14/2018
CellSeed Inc. develops regenerative medicine products. Its operations are carried out through the following business divisions: Cell Sheet Regenerative Medicine and Intelligent Cell Culture Ware Products. The Cell Sheet Regenerative Medicine division provides research, development, marketing, and sale of epithelial cell sheet for corneal and esophageal regeneration; regenerated cardiac patch to treat heart diseases; cell sheet for periodontal tissue regeneration; and regenerated cartilage sheet for the treatment of osteoarthritis.